Current Report Filing (8-k)
June 14 2021 - 5:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2021
Larimar Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36510
|
|
20-3857670
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania
|
|
|
|
19004
|
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (844)
511-9056
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, par value $0.001 per share
|
|
LRMR
|
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On June 14, 2021, Larimar Therapeutics, Inc. (the “Company”) posted on its website an updated slide presentation, which is
attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and
other parties from time to time.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
Below is a list of exhibits included with this
Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
Larimar Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Carole S. Ben-Maimon, M.D.
|
|
|
|
|
|
Name:
|
|
Carole S. Ben-Maimon, M.D.
|
|
Title:
|
|
President and Chief Executive Officer
|
Date: June 14, 2021
Larimar Therapeutics (NASDAQ:LRMR)
Historical Stock Chart
From Oct 2024 to Nov 2024
Larimar Therapeutics (NASDAQ:LRMR)
Historical Stock Chart
From Nov 2023 to Nov 2024
